INTRODUCTION
S ubcutaneous panniculitis-like T-cell lymphoma (SPTCL) is defined as cytotoxic T-cell lymphoma (CTCL) characterized by subcutaneous infiltrate of pleomorphic T-cells. SPTCL category includes cases with alpha/beta T-cell phenotype (75%) and cases with gamma-delta T-cell phenotype (25%) according to the previous classifications. At present, the WHO-European Organization for Research and Treatment of Cancer (EORTC) classifies only α/β phenotype as SPTCL [1] and T-cell receptor γδ is placed in a new category of primary cutaneous peripheral T-cell lymphomas -cutaneous γ T-cell lymphoma. [2] SPTCL is common in the age group of 20-70 years with female predominance and rare in children. [3] We herewith report a case of SPTCL in a 3-year-old child where the lesions resolved with supportive therapy. complete blood picture, liver function test (LFT), renal function test, antistreptolysin O titer, C-reactive protein, antinuclear antibodies, double-stranded DNA, X-ray chest, and U/S of the abdomen were normal. Peripheral smear and bone marrow aspiration were normal. Skin biopsy showed normal epidermis. Dermis showed mild perivascular lymphocytic infiltrate and subcutaneous tissue infiltration by lymphocytes predominantly outlining the adipocytes. Occasional lymphocytes appeared atypical with hyperchromasia. There was no evidence of granuloma or vasculitis [ Figure 3 ]. On immunohistochemical studies, the atypical lymphocytes were positive for CD3 and CD 8 (CD3+, CD8+, CD20−) [ Figure 4 ]. Ki-67 index was high by 50%. Based on histopathological and immunohistochemical findings, a diagnosis of SPTCL was made. Skin lesions resolved in 4 weeks with intravenous amoxicillin and clavulanic acid and supportive therapy with hyperpigmentation. The child was under regular follow-up for the past 4 months without any new lesion.
DISCUSSION
CTCL is a group of lymphoproliferative disorders characterized by localization of neoplastic T-lymphocytes to the skin. The WHO-EORTC classification of CTCLs is divided into those with indolent clinical behavior, those with aggressive subtypes and natural killer-cell lymphoma . CTCLs with indolent clinical behavior include mycosis fungoides and its variants, primary cutaneous CD30+ lymphoproliferative disorder, primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma (provisional), and SPTCL. [4] SPTCL classified as α/β T-cell phenotype (SPTCL-AB) and SPTCL with γδ T-cell phenotype (SPTCL-GD). Both entities are characterized by atypical lymphocytes that involve the subcutis in a lobular configuration with rimming of individual adipocytes. Alpha/beta phenotype is usually CD8+, infiltrates confined to the subcutaneous tissue only and with an indolent clinical course. [5] A similar-appearing lymphoma with γ/δ phenotype is CD4−, CD8−, and CD56+; the infiltration may involve the epidermis and have a poor prognosis. [5] In contrast to the α/β cases, γδ T-cell lymphoma is associated with a more aggressive clinical course and increased risk of developing hemophagocytic syndrome (HPS). HPS is seen in 15-20% of SPTCL and carries poor prognosis. [3] Subcutaneous panniculitis-like lymphoma (SPTCL-AB) represents <1% of all non-Hodgkin lymphomas. It is common in the age group ranging 22-73 years but rare in children. [5] [6] [7] It is characterized by recurrent erythematous subcutaneous nodules and plaques involving the extremities, trunk, and rarely the face. Ulceration is uncommon. [1, 4] These lesions may resemble benign panniculitis and is often accompanied by systemic symptoms such as fever, fatigue, weight loss, hepatitis, and lymphadenopathy. [2] Autoimmune diseases are common among SPTCL patients, particularly systemic lupus erythematosus. The laboratory abnormalities include various cytopenias and elevated LFTs. Histologically, SPTCL is characterized by lobular panniculitis with a subcutaneous atypical lymphocyte proliferation rimming the adipocytes. Early lesions show focal atypical lobular lymphocytic infiltration of the subcutis without epidermal or dermal involvement that may confuse with benign panniculitis. Other inflammatory cells, particularly plasma cells are absent which differentiate it from lupus panniculitis, later rimming of individual fat cells by the neoplastic cells, mitoses, and karyorrhexis. The immune phenotype of atypical lymphocytes is CD3+, CD8+, CD4−, CD30−, and CD56−. [3] SPTCL may be accompanied by HPS characterized by fever, cytopenia, hepatosplenomegaly, and hemophagocytosis (phagocytosis of erythrocytes, leukocytes, platelets, and their precursors by macrophages) in the bone marrow. SPTCL-AB without associated HPS has good prognosis. [3] The 5-year overall survival rate in cases of SPTCL-AB is generally around 82%. [3] Treatment includes systemic agents such as steroids, methotrexate, cyclosporine, bexarotene, and interferon for indolent disease with a generalized distribution whereas aggressive presentations may require combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP regimen) and stem cell transplantation. [2, 4, 8] Indolent localized lesions may respond to local radiotherapy.
SPTCL is a rare entity in children and very few cases have been reported below 3 years of age [9] [10] [11] Ulceration is uncommon in α-β type. Literature survey showed very few case reports of spontaneous resolution [6, 8] in SPTCL which was also observed in our case. Although this child presented with multiple cutaneous lesions along with systemic symptoms, the child showed remission with intravenous antibiotics and supportive therapy. In the early stages, panniculitis-like lymphoma clinically and pathologically may mimic benign panniculitis; hence, early diagnosis, management, and long-term follow-up are necessary for better outcome.
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